Remnant lipoproteins as strong key particles to atherogenesis

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 3, 2009, Pages 145-154

  Fujioka, Yoshio ^a   Ishikawa, Yuichi ^b  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b KOBE UNIVERSITY   (Japan)

Author keywords

Apolipoprotein B 48 (apoB 48); Chylomicron remnants; Postprandial hyperlipidemia; Remnant like particles (RLP)

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN E; CHYLOMICRON REMNANT; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; MACROPHAGE MIGRATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SMOOTH MUSCLE FIBER; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 70350220516     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E598     Document Type: Review

References (77)

1. Kannel WB, Castelli WP, Gordon T, McNamara PM: Serum cholesterol, lipoproteins, and risk of coronary heart disease: The Framingham study. Ann Intern Med, 1971; 74;1-12
2. Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, Shimamoto T, Iida M, Komachi Y: Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol, 2001; 153:490-499
3. Eberly LE, Stamler J, Neaton JD, for the Multiple Risk Factor Intervention Trial Research Group: Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med, 2003; 163;1077-1083
4. Imaizumi K, Fainaru M, Havel RJ: Composition of proteins of mesenteric lymph chylomicrons in the rat and alterations produced upon exposure of chylomicrons to blood serum and serum proteins. J Lipid Res, 1978; 19:712-722
5. Cooper AD: In: Zakim D, Boyer T. editors. Hepatology: a textbook of liver disease. 2nd edn. Vol.1. Philadelphia: WB Saunders; 1989; 96-123
6. Cooper AD: Hepatic uptake of chylomicron remnants. J Lipid Res, 1997; 38:2173-2192
7. Mahley RW, Huang Y: Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. J Clin Invest, 2007; 117:94-98
8. Zilversmit DB: Atherogenesis: a postprandial phenomenon. Circulation, 1979; 60:473-485
9. Scow RO, Egelrud T: Hydrolysis of chylomicron phosphatidylcholine in vitro by lipoprotein lipase, phospholipase A2 and phospholipase C. Biochim Biophys Acta, 1976; 431:538-549
10. Morimoto S, Fujioka Y, Hosoai H, Okumura T, Masai M, Sakoda T, Tsujino T, Ohyanagi M, Iwasaki T: The renin-angiotensin system is involved in the production of plasminogen activator inhibitor type 1 by cultured endothelial cells in response to chylomicron remnants. Hypertens Res, 2003; 26:315-323
11. Liu-Wu Y, Hurt-Camejo E, Wiklund O: Lysophosphatidylcholine induces the production of IL-1beta by human monocytes. Atherosclerosis, 1998; 137:351-357
12. Thomas CE, Jackson RL, Ohlweiler DF, Ku G: Multiple lipid oxidation products in low density lipoproteins induce interleukin-1 beta release from human blood mononuclear cells. J Lipid Res, 1994; 35:417-427
13. Lambert MS, Avella MA, Berhane Y, Shervill E, Botham KM: The fatty acid composition of chylomicron remnants influences their binding and internalization by isolated hepatocytes. Eur J Biochem, 2001; 268:3983-3992
14. Staprans I, Rapp JH, Pan XM, Feingold KR: Oxidized lipids in the diet are incorporated by the liver into very low density lipoprotein in rats. J Lipid Res, 1996; 37:420-430
15. Zheng C, Murdoch SJ, Brunzell JD, Sacks FM: Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans. Arterioscler Thromb Vasc Biol, 2006; 26:891-896
16. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E, Havel RJ: Cholesterol in remnant-like particles in human serum using monoclonal anti apo B-100 and anti A-I immunoaffinity mixed gel. Clin Chim Acta, 1993; 223:53-71
17. Campos E, Nakajima K, Tanaka A, Havel RJ: Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res, 1992; 33:369-380
18. Marcoux C, Tremblay M, Nakajima K, Davignon J, Cohn JS: Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients. J Lipid Res, 1999; 40:636-647
19. Campos E, Kotite L, Blanche P, Mitsugi Y, Frost PH, Masharani U, Krauss RM, Havel RJ: Properties of triglyceride-rich and cholesterol-rich lipoproteins in the remnant-like particle fraction of human blood plasma. J Lipid Res, 2002; 43:365-374
20. Miyauchi K, Kayahara N, Ishigami M, Kuwata H, Mori H, Sugiuchi H, Irie T, Tanaka A, Yamashita S, Yamamura T: Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem, 2007; 53:2128-2135
21. Nakada Y, Kurosawa H, Tohyama J, Inoue Y, Ikewaki K: Increased remnant lipoprotein in patients with coronary artery disease-evaluation utilizing a newly developed remnant assay, remnant lipoproteins cholesterol homogenous assay (RemL-C). J Atheroscler Thromb, 2007; 14:56-64
22. Sato I, Ishikawa Y, Ishimoto A, Katsura S, Toyokawa A, Hayashi F, Kawano S, Fujioka Y, Yamashita S, Kumagai S: Significance of measuring serum concentrations of remnant lipoproteins and apolipoprotein B-48 in fasting period. J Atheroscler Thromb, in press
23. Yu KC, Cooper AD: Postprandial lipoproteins and atherosclerosis. Front Biosci, 2001; 6:D332-D354
24. Tanaka A: Postprandial hyperlipidemia and atherosclerosis. J Atheroscler Thromb, 2004; 11:322-329
25. Devaraj S, Vega G, Lange R, Grundy SM, Jialal I: Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. Am J Med, 1998; 104:445-450
26. Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, Tsunoda R, Sakamoto T, Nakano T, Nakajima K, Ogawa H, Sugiyama S, Yoshimura M, Yasue H: Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation, 1999; 99:2858-2860
27. Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A: Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res, 2001; 42:17-21
28. Imke C, Rodriguez BL, Grove JS, McNamara JR, Waslien C, Katz AR, Willcox B, Yano K, Curb JD: Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study. Arterioscler Thromb Vasc Biol, 2005; 25:1718-1722
29. Watanabe N, Taniguchi T, Taketoh H, Kitagawa Y, Namura H, Yoneda N, Kurimoto Y, Yamada S, Ishikawa Y: Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes Care, 1999; 22:152-156
30. Cohn JS, Marcoux C, Davignon J: Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol, 1999; 19:2474-2486
31. Karpe F: Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med, 1999; 246:341-355
32. Karpe F, Hellénius ML, Hamsten A: Differences in post-prandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease. Metabolism, 1999; 48:301-307
33. Uchida Y, Kurano Y, Ito S: Establishment of monoclonal antibody against human ApoB-48 and measurement of ApoB-48 in serum by ELISA method. J Clin Lab Anal, 1998; 12:289-292
34. Sakai N, Uchida Y, Ohashi K, Hibuse T, Saika Y, Tomari Y, Kihara S, Hiraoka H, Nakamura T, Ito S, Yamashita S, Matsuzawa Y: Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res, 2003; 44:1256-1262
35. Kinoshita M, Kojima M, Matsushima T, Teramoto T: Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta, 2005; 351:115-120
36. Fainaru M, Mahley RW, Hamilton RL, Innerarity TL: Structural and metabolic heterogeneity of beta-very low density lipoproteins from cholesterol-fed dogs and from humans with Type III hyperlipoproteinemia. J Lipid Res, 1982; 23:702-714
37. Daugherty A, Lange LG, Sobel BE, Schonfeld G: Aortic accumulation and plasma clearance of β-VLDL and HDL: effects of diet-induced hypercholesterolemia in rabbits. J Lipid Res, 1985; 26:955-963
38. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardman J, Kotite L, Kunitake ST, Havel RJ, Kane JP: Triglyceride-rich lipoproteins isolated by selective-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb, 1994; 14:1767-1774
39. Proctor SD, Mamo JC: Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol, 2003; 23:1595-1600
40. Mohrschladt MF, Weverling-Rijnsburger AW, de Man FH, Stoeken DJ, Sturk A, Smelt AH, Westendorp RG: Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy. Atherosclerosis, 2000; 148:413-419
41. Van Oostrom AJ, Rabelink TJ, Verseyden C, Sijmonsma TP, Plokker HW, De Jaegere PP, Cabezas MC: Activation of leukocytes by postprandial lipemia in healthy volunteers. Atherosclerosis, 2004; 177:175-182
42. Alipour A, van Oostrom AJ, Izraeljan A, Verseyden C, Collins JM, Frayn KN, Plokker TW, Elte JW, Cabezas MC: Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol, 2008; 28:792-797
43. Reape TJ, Groot PH: Chemokines and atherosclerosis. Atherosclerosis, 1999; 147:213-225
44. Maeno Y, Kashiwagi A, Nishio Y, Takahara N, Kikkawa R: IDL can stimulate atherogenic gene expression in cultured human vascular endothelial cells. Diabetes Res Clin Prac, 2000; 48:127-138
45. Park SY, Lee JH, Kim YK, Kim CD, Rhim BY, Lee WS, Hong KW: Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J Pharmacol Exp Ther, 2005; 312:1241-1248
46. Domoto K, Taniguchi T, Takaishi H, Takahashi T, Fujioka Y, Takahashi A, Ishikawa Y, Yokoyama M: Chylomicron remnants induce monocyte chemoattractant protein-1 expression via p38 MAPK activation in vascular smooth muscle cells. Atherosclerosis, 2003; 171:193-200
47. Takahashi Y, Fujioka Y, Takahashi T, Domoto K, Takahashi A, Taniguchi T, Ishikawa Y, Yokoyama M: Chylomicron remnants regulate early growth response factor-1 in vascular smooth muscle cells. Life Sci, 2005; 77:670-682
48. Silverman ES, Collins T: Pathways of Egr-1-mediated gene transcription in vascular biology. Am J Pathol, 1999; 154:665-670
49. Doi H, Kugiyama K, Oka H, Sugiyama S, Ogata N, Koide SI, Nakamura SI, Yasue H: Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation, 2000; 102:670-676
50. Kawakami A, Tanaka A, Nakajima K, Shimokado K, Yoshida M: Atorvastatin attenuates remnant lipoprotein-induced monocyte adhesion to vascular endothelium under flow conditions. Circ Res, 2002; 91:263-271
51. Eriksson P, Nilsson L, Karpe F, Hamsten A: Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol, 1998; 18:20-26
52. Kawasaki S, Taniguchi T, Fujioka Y, Takahashi A, Takahashi T, Domoto K, Taguchi M, Ishikawa Y, Yokoyama M: Chylomicron remnant induces apoptosis in vascular endothelial cells. Ann N Y Acad Sci, 2000; 902:336-341
53. Shin HK, Kim YK, Kim KY, Lee JH, Hong KW: Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation, 2004; 109:1022-1028
54. Chowienczyk PJ, Watts GF, Wierzbicki AS, Cockcroft JR, Brett SE, Ritter JM: Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity. J Am Coll Cardiol, 1997; 29:964-968
55. Lundman P, Eriksson M, Schenck-Gustafsson K, Karpe F, Tornvall P: Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation, 1997; 96:3266-3268
56. Goulinet S, Chapman MJ: Plasma LDL and HDL sub-species are heterogeneous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids: relevance to oxidative resistance and atherogenesis. Arterioscler Thromb Vasc Biol, 1997; 17:786-796
57. Kugiyama K, Doi H, Motoyama T, Soejima H, Misumi K, Kawano H, Nakagawa O, Yoshimura M, Ogawa H, Matsumura T, Sugiyama S, Nakano T, Nakajima K, Yasue H: Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation, 1998; 97:2519-2526
58. Okumura T, Fujioka Y, Morimoto S, Tsuboi S, Masai M, Tsujino T, Ohyanagi M, Iwasaki T: Eicosapentaenoic acid improves endothelial function in hypertriglyceridemic subjects despite increased lipid oxidizability. Am J Med Sci, 2002; 324:247-253
59. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: modification of low-density lipoprotein that increases its atherogenicity. New Engl J Med, 1989; 320:915-924
60. Pitas RE, Innerarity TL, Mahley RW: Foam cells in explants of atherosclerotic rabbit aortas have receptors for beta-very low density lipoproteins and modified low density lipoproteins. Arteriosclerosis, 1983; 3:2-12
61. Fujioka Y, Cooper AD, Fong LG: Multiple processes are involved in the uptake of chylomicron remnants by mouse peritoneal macrophages. J Lipid Res, 1998; 39:2339-2349
62. Brown ML, Ramprasad MP, Umeda PK, Tanaka A, Kobayashi Y, Watanabe T, Shimoyamada H, Kuo WL, Li R, Song R, Bradley WA, Gianturco SH: A macrophage receptor for apolipoprotein B48: cloning, expression, and atherosclerosis. Proc Natl Acad USA, 2000; 97:7488-7493
63. Kawakami A, Tani M, Chiba T, Yui K, Shinozaki S, Nakajima K, Tanaka A, Shimokado K, Yoshida M: Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism. Arterioscler Thromb Vasc Biol, 2005; 25:424-429
64. Aramaki Y, Mitsuoka H, Toyohara M, Jinnai T, Kanatani K, Nakajima K, Mukai E, Yamada Y, Kita T, Inagaki N, Kume N: Lectin-like oxidized LDL receptor-1 (LOX-1) acts as a receptor for remnant-like lipoprotein particles (RLPs) and mediates RLP-induced migration of vascular smooth muscle cells. Atherosclerosis, 2008; 198:272-279
65. Ellsworth JL, Fong LG, Kraemer FB, Cooper AD: Differences in the processing of chylomicron remnants and β-VLDL by macrophages. J Lipid Res, 1990; 31:1399-1411
66. Tabas I, Lim S, Xu XX, Maxfield FR: Endocytosed β-VLDL and LDL are delivered to different intracellular vesicles in mouse peritoneal macrophages. J Cell Biol, 1990; 111:929-940
67. Tabas I, Myers JN, Innerarity TL, Xu XX, Arnold K, Boyles J, Maxfield FR: The influence of particle size and multiple apoprotein E-receptor interactions on the endocytic targeting of β-VLDL in mouse peritoneal macrophages. J Cell Biol, 1991; 115:1547-1560
68. Libby P: Inflammation in atherosclerosis. Nature, 2002; 420:868-874
69. Okumura T, Fujioka Y, Morimoto S, Masai M, Sakoda T, Tsujino T, Kashiwamura S, Okamura H, Ohyanagi M: Chylomicron remnants stimulate release of interleukin-1β by THP-1 cells. J Atheroscler Thromb, 2006; 13:38-45
70. Schönbeck U, Libby P: CD40 signaling and plaque instability. Circ Res, 2001; 89:1092-1103
71. Kamemura K, Fujioka Y, Takaishi H, Takahashi A, Taniguchi T, Ishikawa Y, Yokoyama M: Chylomicron remnants upregulate CD40 expression via the ERK pathway and a redox-sensitive mechanism in THP-1 cells. Atherosclerosis, 2006; 187:257-264
72. Florén CH, Albers JJ, Bierman EL: Uptake of chylomicron remnants causes cholesterol accumulation in cultured human arterial smooth muscle cells. Biochim Biophys Acta, 1981; 663:336-349
73. Zhao D, Letterman J, Schreiber BM: β-migrating very low density lipoprotein (βVLDL) activates smooth muscle cell mitogen-activated protein (MAP) kinase via G protein-coupled receptor-mediated transactivation of the epidermal growth factor (EGF) receptor: effect of MAP kinase activation on βVLDL plus EGF-induced cell proliferation. J Biol Chem, 2001; 276:30579-30588
74. Kawakami A, Tanaka A, Nakano T, Saniabadi A, Numano F: Stimulation of arterial smooth muscle cell proliferation by remnant lipoprotein particles isolated by immuno-affinity chromatography with anti-apo A-I and anti-apoB-100. Horm Metab Res, 2001; 33:67-72
75. Kawakami A, Tanaka A, Chiba T, Nakajima K, Shimokado K, Yoshida M: Remnant lipoprotein-induced smooth muscle cell proliferation involves epidermal growth factor receptor transactivation. Circulation, 2003; 108:2679-2688
76. Yoshino G, Hirano T, Kazumi T: Treatment of small dense LDL. J Atheroscler Thromb, 2002; 9:266-275
77. Hulthe J, Bokemark L, Wikstrand J, Fagerberg B: The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol, 2000; 20:2140-2147